+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

mRNA Vaccines and RNAi Therapeutics Market By Disease Type, By Route of administration, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 234 Pages
  • July 2022
  • Region: Global
  • Allied Market Research
  • ID: 5671298
UP TO OFF until Nov 15th 2024
The single protein-coding gene known as messenger ribonucleic acid (mRNA) is located in the genome and provides the basis for how cells make proteins. Mammalian cells are used in the laboratory to create mRNA vaccines and treatments, which have positive immunological properties. Some of the most common types of vaccines and therapies include non-replicating, in vivo self-replicating, self-amplifying, and in-vitro dendritic cell non-replicating mRNA. They are administered intravenously to trigger the immune system's virus-detection mechanisms and trigger the production of viral antigen proteins by the cells. The body's immunity is strengthened through enhancing B- and T-cell responses.

The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects. In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.

The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include the Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, and TIBA Biotech.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the mRNA vaccines and RNAi therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global mRNA vaccines and RNAi therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Hereditary transthyretin-mediated amyloidosis genetic
  • Acute hepatic porphyria
  • Primary hyperoxaluria type 1
  • Atherosclerotic cardiovascular disease

By Route of administration

  • IV infusion
  • Subcutaneous

By End user

  • Research Institutes
  • Hospitals and clinics

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Alnylam Pharmaceuticals
  • BioNTech AG
  • Curevac AG
  • Etherna Immunotherapies
  • Ethris GMBH
  • IN-CELL-ART
  • Moderna Therapeutics
  • Sangamo Therapeutics, Inc.
  • Sanofi AG
  • SCM Life Sciences (Argos Therapeutics, Inc. )
  • Sarepta Therapeutics
  • Arcturus Therapeutics
  • Ionis Pharmaceuticals, Inc
  • Nutcracker
  • Tiba Biotech

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Hereditary transthyretin-mediated amyloidosis genetic
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Acute hepatic porphyria
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Primary hyperoxaluria type 1
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Atherosclerotic cardiovascular disease
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 IV infusion
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Subcutaneous
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Research Institutes
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Hospitals and clinics
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Type
7.2.3 North America Market size and forecast, by Route of administration
7.2.4 North America Market size and forecast, by End user
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Disease Type
7.2.5.1.2 Market size and forecast, by Route of administration
7.2.5.1.3 Market size and forecast, by End user
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Type
7.2.5.2.2 Market size and forecast, by Route of administration
7.2.5.2.3 Market size and forecast, by End user
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Type
7.2.5.3.2 Market size and forecast, by Route of administration
7.2.5.3.3 Market size and forecast, by End user
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Type
7.3.3 Europe Market size and forecast, by Route of administration
7.3.4 Europe Market size and forecast, by End user
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Disease Type
7.3.5.1.2 Market size and forecast, by Route of administration
7.3.5.1.3 Market size and forecast, by End user
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Disease Type
7.3.5.2.2 Market size and forecast, by Route of administration
7.3.5.2.3 Market size and forecast, by End user
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Disease Type
7.3.5.3.2 Market size and forecast, by Route of administration
7.3.5.3.3 Market size and forecast, by End user
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Type
7.3.5.4.2 Market size and forecast, by Route of administration
7.3.5.4.3 Market size and forecast, by End user
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Type
7.3.5.5.2 Market size and forecast, by Route of administration
7.3.5.5.3 Market size and forecast, by End user
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Type
7.3.5.6.2 Market size and forecast, by Route of administration
7.3.5.6.3 Market size and forecast, by End user
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Type
7.4.3 Asia-Pacific Market size and forecast, by Route of administration
7.4.4 Asia-Pacific Market size and forecast, by End user
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by Disease Type
7.4.5.1.2 Market size and forecast, by Route of administration
7.4.5.1.3 Market size and forecast, by End user
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by Disease Type
7.4.5.2.2 Market size and forecast, by Route of administration
7.4.5.2.3 Market size and forecast, by End user
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Disease Type
7.4.5.3.2 Market size and forecast, by Route of administration
7.4.5.3.3 Market size and forecast, by End user
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Disease Type
7.4.5.4.2 Market size and forecast, by Route of administration
7.4.5.4.3 Market size and forecast, by End user
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Type
7.4.5.5.2 Market size and forecast, by Route of administration
7.4.5.5.3 Market size and forecast, by End user
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Disease Type
7.4.5.6.2 Market size and forecast, by Route of administration
7.4.5.6.3 Market size and forecast, by End user
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Type
7.5.3 LAMEA Market size and forecast, by Route of administration
7.5.4 LAMEA Market size and forecast, by End user
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Type
7.5.5.1.2 Market size and forecast, by Route of administration
7.5.5.1.3 Market size and forecast, by End user
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Disease Type
7.5.5.2.2 Market size and forecast, by Route of administration
7.5.5.2.3 Market size and forecast, by End user
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Disease Type
7.5.5.3.2 Market size and forecast, by Route of administration
7.5.5.3.3 Market size and forecast, by End user
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Disease Type
7.5.5.4.2 Market size and forecast, by Route of administration
7.5.5.4.3 Market size and forecast, by End user
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Alnylam Pharmaceuticals
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 BioNTech AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Curevac AG
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Etherna Immunotherapies
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Ethris GMBH
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 IN-CELL-ART
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Moderna Therapeutics
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sangamo Therapeutics, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi AG
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 SCM Life Sciences (Argos Therapeutics, Inc. )
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Sarepta Therapeutics
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Arcturus Therapeutics
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Ionis Pharmaceuticals, Inc
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Nutcracker
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Tiba Biotech
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
List of Tables
Table 1. Global Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 2. Winter Sports Equiment Market Size, for Ski Equipment, by Region, 2021-2031 ($Million)
Table 3. Winter Sports Equiment Market for Ski Equipment by Country, 2021-2031 ($Million)
Table 4. Winter Sports Equiment Market Size, for Footwear, by Region, 2021-2031 ($Million)
Table 5. Winter Sports Equiment Market for Footwear by Country, 2021-2031 ($Million)
Table 6. Winter Sports Equiment Market Size, for Protective Gear, by Region, 2021-2031 ($Million)
Table 7. Winter Sports Equiment Market for Protective Gear by Country, 2021-2031 ($Million)
Table 8. Winter Sports Equiment Market Size, for Other, by Region, 2021-2031 ($Million)
Table 9. Winter Sports Equiment Market for Other by Country, 2021-2031 ($Million)
Table 10. Global Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 11. Winter Sports Equiment Market Size, for Snowboarding, by Region, 2021-2031 ($Million)
Table 12. Winter Sports Equiment Market for Snowboarding by Country, 2021-2031 ($Million)
Table 13. Winter Sports Equiment Market Size, for Skiing, by Region, 2021-2031 ($Million)
Table 14. Winter Sports Equiment Market for Skiing by Country, 2021-2031 ($Million)
Table 15. Winter Sports Equiment Market Size, for Ice Hockey, by Region, 2021-2031 ($Million)
Table 16. Winter Sports Equiment Market for Ice Hockey by Country, 2021-2031 ($Million)
Table 17. Winter Sports Equiment Market Size, for Others, by Region, 2021-2031 ($Million)
Table 18. Winter Sports Equiment Market for Others by Country, 2021-2031 ($Million)
Table 19. Global Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 20. Winter Sports Equiment Market Size, for Online, by Region, 2021-2031 ($Million)
Table 21. Winter Sports Equiment Market for Online by Country, 2021-2031 ($Million)
Table 22. Winter Sports Equiment Market Size, for Offline, by Region, 2021-2031 ($Million)
Table 23. Winter Sports Equiment Market for Offline by Country, 2021-2031 ($Million)
Table 24. Winter Sports Equiment Market, by Region, 2021-2031 ($Million)
Table 25. North America Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 26. North America Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 27. North America Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 28. North America Winter Sports Equiment Market, by Country, 2021-2031 ($Million)
Table 29. U.S. Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 30. U.S. Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 31. U.S. Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 32. Canada Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 33. Canada Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 34. Canada Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 35. Mexico Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 36. Mexico Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 37. Mexico Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 38. Europe Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 39. Europe Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 40. Europe Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 41. Europe Winter Sports Equiment Market, by Country, 2021-2031 ($Million)
Table 42. Germany Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 43. Germany Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 44. Germany Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 45. Poland Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 46. Poland Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 47. Poland Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 48. France Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 49. France Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 50. France Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 51. U.K. Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 52. U.K. Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 53. U.K. Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 54. Austria Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 55. Austria Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 56. Austria Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 57. Italy Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 58. Italy Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 59. Italy Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 60. Switzerland Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 61. Switzerland Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 62. Switzerland Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 63. Sweden Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 64. Sweden Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 65. Sweden Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 66. Spain Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 67. Spain Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 68. Spain Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 69. Russia Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 70. Russia Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 71. Russia Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 72. Norway Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 73. Norway Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 74. Norway Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 75. Denmark Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 76. Denmark Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 77. Denmark Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 78. Czech Republic Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 79. Czech Republic Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 80. Czech Republic Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 81. Hungary Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 82. Hungary Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 83. Hungary Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 84. Finland Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 85. Finland Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 86. Finland Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 87. Ireland Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 88. Ireland Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 89. Ireland Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 90. Belgium Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 91. Belgium Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 92. Belgium Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 93. Netherlands Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 94. Netherlands Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 95. Netherlands Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 96. Luxembourg Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 97. Luxembourg Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 98. Luxembourg Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 99. Portugal Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 100. Portugal Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 101. Portugal Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 102. Rest of Europe Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 103. Rest of Europe Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 104. Rest of Europe Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 105. Asia-Pacific Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 106. Asia-Pacific Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 107. Asia-Pacific Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 108. Asia-Pacific Winter Sports Equiment Market, by Country, 2021-2031 ($Million)
Table 109. China Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 110. China Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 111. China Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 112. India Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 113. India Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 114. India Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 115. Australia Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 116. Australia Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 117. Australia Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 118. Japan Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 119. Japan Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 120. Japan Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 121. Malaysia Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 122. Malaysia Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 123. Malaysia Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 124. Thailand Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 125. Thailand Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 126. Thailand Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 127. Singapore Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 128. Singapore Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 129. Singapore Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 130. South Korea Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 131. South Korea Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 132. South Korea Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 133. Rest of Asia-Pacific Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 134. Rest of Asia-Pacific Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 135. Rest of Asia-Pacific Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 136. LAMEA Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 137. LAMEA Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 138. LAMEA Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 139. LAMEA Winter Sports Equiment Market, by Country, 2021-2031 ($Million)
Table 140. Brazil Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 141. Brazil Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 142. Brazil Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 143. Argentina Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 144. Argentina Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 145. Argentina Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 146. United Arab Emirates Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 147. United Arab Emirates Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 148. United Arab Emirates Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 149. Rest of LAMEA Winter Sports Equiment Market, by Product Type, 2021-2031 ($Million)
Table 150. Rest of LAMEA Winter Sports Equiment Market, by Sports, 2021-2031 ($Million)
Table 151. Rest of LAMEA Winter Sports Equiment Market, by Distribution Channel, 2021-2031 ($Million)
Table 152. Alpina Sports: Company Snapshot
Table 153. Alpina Sports: Operating Segments
Table 154. Alpina Sports: Product Portfolio
Table 155. Alpina Sports: Net Sales
Table 156. Alpina Sports: Key Stratergies
Table 157. Amer Sports: Company Snapshot
Table 158. Amer Sports: Operating Segments
Table 159. Amer Sports: Product Portfolio
Table 160. Amer Sports: Net Sales
Table 161. Amer Sports: Key Stratergies
Table 162. Bauer Hockey, LLC: Company Snapshot
Table 163. Bauer Hockey, LLC: Operating Segments
Table 164. Bauer Hockey, LLC: Product Portfolio
Table 165. Bauer Hockey, LLC: Net Sales
Table 166. Bauer Hockey, LLC: Key Stratergies
Table 167. Black Crows: Company Snapshot
Table 168. Black Crows: Operating Segments
Table 169. Black Crows: Product Portfolio
Table 170. Black Crows: Net Sales
Table 171. Black Crows: Key Stratergies
Table 172. Clarus Corporation: Company Snapshot
Table 173. Clarus Corporation: Operating Segments
Table 174. Clarus Corporation: Product Portfolio
Table 175. Clarus Corporation: Net Sales
Table 176. Clarus Corporation: Key Stratergies
Table 177. Elan, D.O.O.: Company Snapshot
Table 178. Elan, D.O.O.: Operating Segments
Table 179. Elan, D.O.O.: Product Portfolio
Table 180. Elan, D.O.O.: Net Sales
Table 181. Elan, D.O.O.: Key Stratergies
Table 182. Fischer Sports GmbH: Company Snapshot
Table 183. Fischer Sports GmbH: Operating Segments
Table 184. Fischer Sports GmbH: Product Portfolio
Table 185. Fischer Sports GmbH: Net Sales
Table 186. Fischer Sports GmbH: Key Stratergies
Table 187. Head UK Ltd.: Company Snapshot
Table 188. Head UK Ltd.: Operating Segments
Table 189. Head UK Ltd.: Product Portfolio
Table 190. Head UK Ltd.: Net Sales
Table 191. Head UK Ltd.: Key Stratergies
Table 192. Icelantic Skis: Company Snapshot
Table 193. Icelantic Skis: Operating Segments
Table 194. Icelantic Skis: Product Portfolio
Table 195. Icelantic Skis: Net Sales
Table 196. Icelantic Skis: Key Stratergies
Table 197. K2 Sports LLC: Company Snapshot
Table 198. K2 Sports LLC: Operating Segments
Table 199. K2 Sports LLC: Product Portfolio
Table 200. K2 Sports LLC: Net Sales
Table 201. K2 Sports LLC: Key Stratergies
Table 202. Mdv Sports: Company Snapshot
Table 203. Mdv Sports: Operating Segments
Table 204. Mdv Sports: Product Portfolio
Table 205. Mdv Sports: Net Sales
Table 206. Mdv Sports: Key Stratergies
Table 207. Rossignol Group: Company Snapshot
Table 208. Rossignol Group: Operating Segments
Table 209. Rossignol Group: Product Portfolio
Table 210. Rossignol Group: Net Sales
Table 211. Rossignol Group: Key Stratergies
Table 212. Tecnica Group S.P.A.: Company Snapshot
Table 213. Tecnica Group S.P.A.: Operating Segments
Table 214. Tecnica Group S.P.A.: Product Portfolio
Table 215. Tecnica Group S.P.A.: Net Sales
Table 216. Tecnica Group S.P.A.: Key Stratergies
Table 217. Scott Sports Sa: Company Snapshot
Table 218. Scott Sports Sa: Operating Segments
Table 219. Scott Sports Sa: Product Portfolio
Table 220. Scott Sports Sa: Net Sales
Table 221. Scott Sports Sa: Key Stratergies
Table 222. Under Armour Inc: Company Snapshot
Table 223. Under Armour Inc: Operating Segments
Table 224. Under Armour Inc: Product Portfolio
Table 225. Under Armour Inc: Net Sales
Table 226. Under Armour Inc: Key Stratergies
Table 227. Völkl Int. GmbH: Company Snapshot
Table 228. Völkl Int. GmbH: Operating Segments
Table 229. Völkl Int. GmbH: Product Portfolio
Table 230. Völkl Int. GmbH: Net Sales
Table 231. Völkl Int. GmbH: Key Stratergies
List of Figures
Figure 1. Mrna Vaccines and Rnai Therapeutics Market Segmentation
Figure 2. Mrna Vaccines and Rnai Therapeutics Market,2021-2031
Figure 3. Mrna Vaccines and Rnai Therapeutics Market,2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Mrna Vaccines and Rnai Therapeutics Market:Drivers, Restraints and Opportunities
Figure 12. Mrna Vaccines and Rnai Therapeutics Market,By Disease Type,2021(%)
Figure 13. Comparative Share Analysis of Hereditary Transthyretin-Mediated Amyloidosis Genetic Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 14. Comparative Share Analysis of Acute Hepatic Porphyria Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 15. Comparative Share Analysis of Primary Hyperoxaluria Type 1 Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 16. Comparative Share Analysis of Atherosclerotic Cardiovascular Disease Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 17. Mrna Vaccines and Rnai Therapeutics Market,By Route of Administration,2021(%)
Figure 18. Comparative Share Analysis of IV Infusion Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 19. Comparative Share Analysis of Subcutaneous Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 20. Mrna Vaccines and Rnai Therapeutics Market,By End-user,2021(%)
Figure 21. Comparative Share Analysis of Research Institutes Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 22. Comparative Share Analysis of Hospitals and Clinics Mrna Vaccines and Rnai Therapeutics Market,2021-2031(%)
Figure 23. Mrna Vaccines and Rnai Therapeutics Market by Region,2021
Figure 24. U.S. Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 25. Canada Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 26. Mexico Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 27. Germany Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 28. France Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 29. U.K. Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 30. Italy Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 31. Spain Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 32. Rest of Europe Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 33. China Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 34. Japan Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 35. India Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 36. Australia Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 37. South Korea Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 38. Rest of Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 39. Brazil Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 40. Saudi Arabia Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 41. South Africa Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 42. Rest of LAMEA Mrna Vaccines and Rnai Therapeutics Market,2021-2031($Million)
Figure 43. Top Winning Strategies, by Year
Figure 44. Top Winning Strategies, by Development
Figure 45. Top Winning Strategies, by Company
Figure 46. Product Mapping of Top 10 Players
Figure 47. Competitive Dashboard
Figure 48. Competitive Heatmap of Top 10 Key Players
Figure 49. Alnylam Pharmaceuticals.: Net Sales ,($Million)
Figure 50. Biontech AG.: Net Sales ,($Million)
Figure 51. Curevac AG.: Net Sales ,($Million)
Figure 52. Etherna Immunotherapies.: Net Sales ,($Million)
Figure 53. Ethris GmbH.: Net Sales ,($Million)
Figure 54. In-Cell-Art.: Net Sales ,($Million)
Figure 55. Moderna Therapeutics.: Net Sales ,($Million)
Figure 56. Sangamo Therapeutics, Inc..: Net Sales ,($Million)
Figure 57. Sanofi AG.: Net Sales ,($Million)
Figure 58. Scm Life Sciences (Argos Therapeutics, Inc. ).: Net Sales ,($Million)
Figure 59. Sarepta Therapeutics.: Net Sales ,($Million)
Figure 60. Arcturus Therapeutics.: Net Sales ,($Million)
Figure 61. Ionis Pharmaceuticals, Inc.: Net Sales ,($Million)
Figure 62. Nutcracker.: Net Sales ,($Million)
Figure 63. Tiba Biotech.: Net Sales ,($Million)

Executive Summary

According to the report, titled, “mRNA Vaccines and RNAi Therapeutics Market," the mRNA vaccines and RNAi therapeutics market was valued at $707.97 million in 2021, and is estimated to reach $12.31 billion by 2031, growing at a CAGR of 31.3% from 2022 to 2031.

mRNA vaccines and RNAi therapeutics have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, there has been development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines and RNAi therapeutics are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Thus, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nano emulsion), naked mRNA vaccines and dendritic cell-based mRNA vaccines.

The key factors that drive the mRNA vaccines and RNAi therapeutics market growth is increase in prevalence of chronic disease and infectious disease, initiatives taken by government for large scale sequencing projects.

In addition, target specialty and selectivity of treatment and increasing awareness about vaccination are some mRNA vaccines and RNAi therapeutics market trends which further expected to boost the mRNA vaccines and RNAi therapeutics market size growth during forecast period. However, high cost of research, threat of failure and challenges in quantification of mRNA is expected to hamper the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, applications of mRNA technology and development of mRNA biomarker are expected to provide numerous opportunities for market growth during the forecast period.

By disease type, the hereditary transthyretin-mediated amyloidosis genetic segment dominated the mRNA vaccines and RNAi therapeutics market share in 2021 and is expected to remain dominant during the forecast period. This is attributed to the rise in demand for the treatment of ATTR amyloidosis owing to, increase in prevalence and increasing need for the treatment of fatal disease. In addition, increase in awareness, improvement in diagnostic procedures, improvement in health care services, rapid economic growth in developing countries, and rise in R&D activities further boost the market growth. On the other side, Atherosclerotic cardiovascular disease is projected to exhibit the fastest market growth during the forecast period, owing to high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries.

Depending on route of administration, the IV infusion segment was the major revenue contributor in mRNA vaccines industry and RNAi therapeutics industry, and is anticipated to continue this trend during the forecast period, owing to increase in adoption of IV infusion for administration of vaccines and therapeutics. On the other side, subcutaneous segment is projected to exhibit the fastest market growth during the forecast period owing to cost effectiveness of subcutaneous route of administration as compare to IV infusion.

By end user, the hospitals & clinics segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to increase in number of patients with respiratory disease, cancer and infectious disease. Furthermore, the research institutes segment is projected to show fastest growth during the forecast period, due to collaboration of research organizations and research institutes or collaborating with government bodies to bear the high cost of research.

Region wise, North America has the highest market share in 2021 registering a CAGR of 31.1% during the forecast period. This is attributed to the well-established healthcare system, increase in number of geriatric patients, and supportive reimbursement policies in healthcare system and increasing number of healthcare facilities offering mRNA vaccines and RNAi therapeutics. Asia-Pacific is projected to register the highest CAGR of 33.9% during the forecast period. The presence of a large population base, increasing per capita income, growing medical tourism industry, and rising public awareness regarding benefits of mRNA vaccine and RNAi therapeutics are the key driving factors that boost the growth of the market in the region.

Key Findings of the Study

  • On the basis of disease type, the hereditary transthyretin-mediated amyloidosis genetic segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
  • On the basis of route of administration, the IV infusion segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
  • Depending on end user, hospitals and clinics segment is projected to grow at a CAGR of 31.6% during the forecast period.
  • Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 33.9% during the forecast period.

Companies Mentioned

  • Alnylam Pharmaceuticals
  • Biontech AG
  • Curevac AG
  • Etherna Immunotherapies
  • Ethris GmbH
  • In-Cell-Art
  • Moderna Therapeutics
  • Sangamo Therapeutics, Inc.
  • Sanofi AG
  • Scm Life Sciences (Argos Therapeutics, Inc. )
  • Sarepta Therapeutics
  • Arcturus Therapeutics
  • Ionis Pharmaceuticals, Inc
  • Nutcracker
  • Tiba Biotech

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...